BASEL, Switzerland & SUWON, South Korea--(BUSINESS WIRE)--Under the agreement, Alentis and PinotBio will discover and develop next-generation antibody-drug conjugates targeting claudin-1 for oncology.
Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1
